MX2019003029A - Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano. - Google Patents
Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano.Info
- Publication number
- MX2019003029A MX2019003029A MX2019003029A MX2019003029A MX2019003029A MX 2019003029 A MX2019003029 A MX 2019003029A MX 2019003029 A MX2019003029 A MX 2019003029A MX 2019003029 A MX2019003029 A MX 2019003029A MX 2019003029 A MX2019003029 A MX 2019003029A
- Authority
- MX
- Mexico
- Prior art keywords
- lilotomab
- treatment
- hodgkin lymphoma
- satetraxetan
- lilotomab satetraxetan
- Prior art date
Links
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 title abstract 2
- 229940126616 lilotomab satetraxetan Drugs 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 229950001237 lilotomab Drugs 0.000 title 1
- 238000002203 pretreatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16189191 | 2016-09-16 | ||
| EP17164164 | 2017-03-31 | ||
| EP17170641 | 2017-05-11 | ||
| EP17175768 | 2017-06-13 | ||
| PCT/EP2017/073336 WO2018050851A1 (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003029A true MX2019003029A (es) | 2019-09-13 |
Family
ID=59895313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003029A MX2019003029A (es) | 2016-09-16 | 2017-09-15 | Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190192703A1 (enExample) |
| EP (1) | EP3512881A1 (enExample) |
| JP (1) | JP2019529433A (enExample) |
| KR (1) | KR20190054113A (enExample) |
| CN (1) | CN109790219A (enExample) |
| AU (1) | AU2017327772A1 (enExample) |
| BR (1) | BR112019004838A2 (enExample) |
| CA (1) | CA3035268A1 (enExample) |
| IL (1) | IL265387A (enExample) |
| MX (1) | MX2019003029A (enExample) |
| PH (1) | PH12019550033A1 (enExample) |
| RU (1) | RU2019110955A (enExample) |
| SG (2) | SG10202102588QA (enExample) |
| WO (1) | WO2018050851A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019028301A1 (en) * | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL |
| US20210106703A1 (en) * | 2017-11-22 | 2021-04-15 | Nordic Nanovector Asa | Radioimmunoconjugates in combination with other drugs as treatment against nhl |
| KR20240083769A (ko) | 2022-12-05 | 2024-06-12 | 김원석 | 휴대할 수 있는 해수 정화 유닛용 물통 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001010462A1 (en) * | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| HK1203372A1 (en) * | 2011-12-13 | 2015-10-30 | Nordic Nanovector Asa | Chimeric therapeutic anti - cd37 antibodie hh1 |
| KR102624023B1 (ko) * | 2015-02-24 | 2024-01-11 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 결합-촉발된 전사 스위치 및 이들의 이용 방법 |
-
2017
- 2017-09-15 JP JP2019515291A patent/JP2019529433A/ja active Pending
- 2017-09-15 WO PCT/EP2017/073336 patent/WO2018050851A1/en not_active Ceased
- 2017-09-15 CN CN201780055437.7A patent/CN109790219A/zh active Pending
- 2017-09-15 SG SG10202102588QA patent/SG10202102588QA/en unknown
- 2017-09-15 US US16/329,661 patent/US20190192703A1/en not_active Abandoned
- 2017-09-15 KR KR1020197010585A patent/KR20190054113A/ko not_active Ceased
- 2017-09-15 EP EP17768448.7A patent/EP3512881A1/en not_active Withdrawn
- 2017-09-15 SG SG11201901672RA patent/SG11201901672RA/en unknown
- 2017-09-15 MX MX2019003029A patent/MX2019003029A/es unknown
- 2017-09-15 AU AU2017327772A patent/AU2017327772A1/en not_active Abandoned
- 2017-09-15 RU RU2019110955A patent/RU2019110955A/ru unknown
- 2017-09-15 CA CA3035268A patent/CA3035268A1/en active Pending
- 2017-09-15 BR BR112019004838A patent/BR112019004838A2/pt not_active IP Right Cessation
-
2019
- 2019-03-07 PH PH12019550033A patent/PH12019550033A1/en unknown
- 2019-03-14 IL IL265387A patent/IL265387A/en unknown
-
2021
- 2021-06-22 US US17/304,541 patent/US20220160907A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019110955A (ru) | 2020-10-20 |
| SG11201901672RA (en) | 2019-03-28 |
| KR20190054113A (ko) | 2019-05-21 |
| AU2017327772A1 (en) | 2019-03-21 |
| US20190192703A1 (en) | 2019-06-27 |
| US20220160907A1 (en) | 2022-05-26 |
| CN109790219A (zh) | 2019-05-21 |
| JP2019529433A (ja) | 2019-10-17 |
| SG10202102588QA (en) | 2021-04-29 |
| EP3512881A1 (en) | 2019-07-24 |
| BR112019004838A2 (pt) | 2019-06-04 |
| CA3035268A1 (en) | 2018-03-22 |
| WO2018050851A1 (en) | 2018-03-22 |
| PH12019550033A1 (en) | 2019-07-29 |
| IL265387A (en) | 2019-05-30 |
| RU2019110955A3 (enExample) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551397A1 (en) | Cot modulators and methods of use thereof | |
| PH12019501227A1 (en) | Synthetic immune receptors and methods of use thereof | |
| MX2021010528A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| EA201592105A1 (ru) | Толерогенные синтетические наноносители и терапевтические макромолекулы для снижения или усиления фармакодинамических эффектов | |
| MX2016011619A (es) | Anticuerpos anti-egfrviii y usos de los mismos. | |
| PH12015502659A1 (en) | Surface treatment compositions comprising photochromic dyes | |
| TW201614068A (en) | Fucosidase from bacteroides and methods using the same | |
| NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
| MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
| HK1220980A1 (zh) | 用於治疗庞贝氏症的方法和组合物 | |
| EA201591674A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX382337B (es) | Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias. | |
| MX370573B (es) | Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer. | |
| MX2015013177A (es) | Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki. | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| MX2017017124A (es) | 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot). | |
| EA201692284A1 (ru) | Ниацинамид для стимуляции продуцирования антимикробных пептидов | |
| MX2020004411A (es) | Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren. | |
| AU350280S (en) | Apparatus for skin treatment | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| PH12016500465B1 (en) | Deoxynojirimycin derivatives and methods of their using | |
| PH12019550033A1 (en) | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan | |
| ZA201907623B (en) | T cells with reduced surface fucosylation and methods of making and using the same | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions |